Gensight Biologics S.a annual stock-based compensation
2020
2021
2022
2023
2024
2025
Gensight Biologics S.a Stock-Based Compensation Growth & History (SIGHT)
Gensight Biologics S.a's stock-based compensation was €391,000 for fiscal 2025.
View full Gensight Biologics S.a company overviewGensight Biologics S.a annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €391,000 | −€393,000 | −50.13% |
| 2024 | 2024-12-31 | €784,000 | €197,000 | +33.56% |
| 2023 | 2023-12-31 | €587,000 | −€2.8M | −82.55% |
| 2022 | 2022-12-31 | €3.4M | −€1.5M | −30.41% |
| 2021 | 2021-12-31 | €4.8M | €1.4M | +39.91% |
| 2020 | 2020-12-31 | €3.5M | — | — |
Gensight Biologics S.a stock-based compensation trends
Over the last five fiscal years, Gensight Biologics S.a's stock-based compensation decreased from €3.5M to €391,000, a change of −€3.1M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
reported stock-based compensation
TickerStat standardizes share-based compensation reported in company official filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gensight Biologics S.a source filings ↗Community posts
GenSight advances LUMEVOQ manufacturing transfer to Catalent
GenSight ($SIGHT) said an engineering batch of GS010/LUMEVOQ at Catalent was produced as planned, with viral genome concentration meeting target specifications. Preparations have begun for a GMP-standard batch to supply special-access progr ...